Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data

Moderna shares fell nearly 20% Thursday after late-stage melanoma-vaccine trial data appeared online ahead of its scheduled Saturday release; Merck shares slipped 2%. The Phase 3 results said Intismeran plus Keytruda reduced the risk of recurrence or death by 42%, and analysts described the data as encouraging while suggesting high investor expectations may explain the selloff. Despite the decline, Moderna shares remain up nearly 600% year to date and Merck shares are up 40%.

Analysis

The gap between a 42% relative risk reduction and the market’s required evidence is the key issue: without absolute recurrence rates, follow-up duration, subgroup consistency, and incremental toxicity, investors cannot yet translate the result into eligible patients or commercial value. The sharp MRNA reaction, after a major prior rerating, is consistent with expectations resetting rather than proof that the trial failed. Treat the company release as preliminary until the ESMO presentation supplies the full dataset.

Moderna has the more direct valuation sensitivity: success could establish a differentiated oncology franchise, but any revenue contribution depends on regulatory review, adoption, and the partners’ economics, none of which are established here. Merck’s exposure is more buffered by its broader business; a successful add-on could extend Keytruda’s relevance in earlier-stage treatment, while disappointing safety or durability data would mainly weaken this incremental option. Competitors including Bristol Myers Squibb and Roche could benefit if clinicians or payers favor established alternatives, but that depends on comparative outcomes not provided.

Near term, expect event-driven volatility through the full-data release. Over 1–3 months, absolute benefit and safety will drive analyst model revisions; over 6–18 months, regulatory and commercial execution matter more than this headline. The contrarian risk is that the selloff overprices a strong relative endpoint; the opposing risk is that a large relative effect masks modest absolute benefit or tolerability trade-offs.

Key Decisions for Investors

• Avoid chasing MRNA’s post-drop bounce before the full ESMO dataset. Reassess after checking absolute recurrence rates, duration of follow-up, adverse events, and consistency across patient subgroups; these are the missing inputs that determine clinical and commercial significance.
• For event-driven exposure, consider only a small, defined-risk MRNA position after the presentation if the absolute benefit is meaningful, safety is acceptable, and the shares remain under pressure. Do not infer a price target from the relative-risk figure alone.
• Treat an MRNA-versus-MRK pair as a conditional expression, not an immediate trade: MRNA is the higher-sensitivity leg, while MRK’s broader business may dampen trial-specific moves. Revisit only if the data disappoint and MRNA’s decline fails to reflect that deterioration; the article provides no valuation or collaboration-economics data to size the pair confidently.
• Falsifiers: a small absolute benefit, emerging safety concerns, weak durability, or management commentary that narrows the eligible population would undermine the bullish MRNA thesis. A robust absolute benefit with manageable toxicity and a clear path to regulatory review would challenge the view that the selloff was justified.